223 related articles for article (PubMed ID: 17255354)
1. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.
Colla S; Zhan F; Xiong W; Wu X; Xu H; Stephens O; Yaccoby S; Epstein J; Barlogie B; Shaughnessy JD
Blood; 2007 May; 109(10):4470-7. PubMed ID: 17255354
[TBL] [Abstract][Full Text] [Related]
2. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
Tian E; Zhan F; Walker R; Rasmussen E; Ma Y; Barlogie B; Shaughnessy JD
N Engl J Med; 2003 Dec; 349(26):2483-94. PubMed ID: 14695408
[TBL] [Abstract][Full Text] [Related]
3. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.
Bjorklund CC; Ma W; Wang ZQ; Davis RE; Kuhn DJ; Kornblau SM; Wang M; Shah JJ; Orlowski RZ
J Biol Chem; 2011 Apr; 286(13):11009-20. PubMed ID: 21189262
[TBL] [Abstract][Full Text] [Related]
4. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.
Chen L; Wang S; Zhou Y; Wu X; Entin I; Epstein J; Yaccoby S; Xiong W; Barlogie B; Shaughnessy JD; Zhan F
Blood; 2010 Jan; 115(1):61-70. PubMed ID: 19837979
[TBL] [Abstract][Full Text] [Related]
5. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
6. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.
Zhou F; Meng S; Song H; Claret FX
Blood Rev; 2013 Nov; 27(6):261-7. PubMed ID: 24054128
[TBL] [Abstract][Full Text] [Related]
7. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.
Haaber J; Abildgaard N; Knudsen LM; Dahl IM; Lodahl M; Thomassen M; Kerndrup GB; Rasmussen T
Br J Haematol; 2008 Jan; 140(1):25-35. PubMed ID: 18005268
[TBL] [Abstract][Full Text] [Related]
8. Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Leuk Lymphoma; 2014 Apr; 55(4):911-9. PubMed ID: 23915193
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma.
Kocemba KA; Groen RW; van Andel H; Kersten MJ; Mahtouk K; Spaargaren M; Pals ST
PLoS One; 2012; 7(2):e30359. PubMed ID: 22363428
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma.
Xu Y; Guo J; Liu J; Xie Y; Li X; Jiang H; Wang J; Peng Z; Wang J; Wang S; Wan C; Chen L; Zhong Y; Liu B; Liu Z
Oncogene; 2021 Feb; 40(7):1231-1241. PubMed ID: 33420361
[TBL] [Abstract][Full Text] [Related]
11. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.
Qiang YW; Chen Y; Stephens O; Brown N; Chen B; Epstein J; Barlogie B; Shaughnessy JD
Blood; 2008 Jul; 112(1):196-207. PubMed ID: 18305214
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
13. Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model.
Park BM; Kim EJ; Nam HJ; Zhang D; Bae CH; Kang M; Kim H; Lee W; Bogen B; Lim SK
Yonsei Med J; 2017 May; 58(3):505-513. PubMed ID: 28332354
[TBL] [Abstract][Full Text] [Related]
14. Role of Dickkopf-1, an antagonist of the Wnt/beta-catenin signaling pathway, in estrogen-induced neuroprotection and attenuation of tau phosphorylation.
Zhang QG; Wang R; Khan M; Mahesh V; Brann DW
J Neurosci; 2008 Aug; 28(34):8430-41. PubMed ID: 18716201
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
Manni S; Carrino M; Manzoni M; Gianesin K; Nunes SC; Costacurta M; Tubi LQ; Macaccaro P; Taiana E; Cabrelle A; Barilà G; Martines A; Zambello R; Bonaldi L; Trentin L; Neri A; Semenzato G; Piazza F
Oncotarget; 2017 Feb; 8(9):14604-14619. PubMed ID: 28099937
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.
Fowler JA; Mundy GR; Lwin ST; Edwards CM
Cancer Res; 2012 May; 72(9):2183-9. PubMed ID: 22374979
[TBL] [Abstract][Full Text] [Related]
17. An unexpected role for a Wnt-inhibitor: Dickkopf-1 triggers a novel cancer survival mechanism through modulation of aldehyde-dehydrogenase-1 activity.
Krause U; Ryan DM; Clough BH; Gregory CA
Cell Death Dis; 2014 Feb; 5(2):e1093. PubMed ID: 24577091
[TBL] [Abstract][Full Text] [Related]
18. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation.
Guo J; Liu M; Yang D; Bouxsein ML; Saito H; Galvin RJ; Kuhstoss SA; Thomas CC; Schipani E; Baron R; Bringhurst FR; Kronenberg HM
Cell Metab; 2010 Feb; 11(2):161-71. PubMed ID: 20142103
[TBL] [Abstract][Full Text] [Related]
19. [Bone marrow plasma concentrations of Dickkopf1 in patients with multiple myeloma].
Dun XY; Jiang H; Hou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 38(5):453-8. PubMed ID: 19830856
[TBL] [Abstract][Full Text] [Related]
20. Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression.
Gowda PS; Wildman BJ; Trotter TN; Xu X; Hao X; Hassan MQ; Yang Y
Mol Cancer Res; 2018 Jul; 16(7):1138-1148. PubMed ID: 29592898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
